In another real-world, retrospective head-to-head study on a total of 948,342 T2D subjects, GLP-1 RA had a lower risk of MALE (HR 0.63, 95% CI 0.41–0.96) and MACE (HR 0.62, 95% CI 0.51–0.76) when compared to DPP-4 inhibitors [98]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.